Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TERN

Terns Pharmaceuticals Inc

Sep 12 • 04:00PM ET

7.23

-0.21 -2.82 %

Healthcare • Biotechnology • USA • NASD

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: IWM VTI IWN VXF IBB VTWO DFAS IWC DFAT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.05	Insider Own	20.49%	Shs Outstand	87.47M	Perf Week	0.14%
Market Cap	632.70M	Forward P/E	-	EPS next Y	-1.25	Insider Trans	0.26%	Shs Float	69.58M	Perf Month	11.40%
Enterprise Value	318.39M	PEG	-	EPS next Q	-0.30	Inst Own	77.72%	Short Float	11.29%	Perf Quarter	83.97%
Income	-91.75M	P/S	-	EPS this Y	-0.39%	Inst Trans	-2.41%	Short Ratio	7.48	Perf Half Y	109.57%
Sales	0.00M	P/B	2.07	EPS next Y	-11.60%	ROA	-33.28%	Short Interest	7.86M	Perf YTD	30.51%
Book/sh	3.49	P/C	2.01	EPS next 5Y	-8.16%	ROE	-35.02%	52W High	11.00 -34.27%	Perf Year	-35.62%
Cash/sh	3.60	P/FCF	-	EPS past 3/5Y	17.43% 16.38%	ROIC	-29.99%	52W Low	1.87 287.67%	Perf 3Y	90.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.73% 6.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	20.37%	Oper. Margin	-	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.88	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	24.70	EPS Q/Q	13.85%	SMA20	2.22%	Beta	-0.04	Target Price	15.57
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	16.73%	Rel Volume	1.78	Prev Close	7.44
Employees	59	LT Debt/Eq	0.00	Earnings	Aug 05 AMC	SMA200	57.43%	Avg Volume	1.05M	Price	7.23
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.44% -	Trades		Volume	1,872,376	Change	-2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Resumed	H.C. Wainwright	Neutral
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Aug-21-25 04:05PM	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 (GlobeNewswire) +7.30%
Aug-07-25 09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
Aug-05-25 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +5.74% -6.74%
Aug-04-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.12%
Jun-23-25 04:07PM	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire) -5.64%
04:05PM	Loading…
May-29-25 04:05PM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire)
May-09-25 07:54AM	Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 04:05PM	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.71%
Apr-30-25 04:05PM	Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire) +6.11% +7.88%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-07-25 09:35AM	Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
Apr-03-25 09:35AM	Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) (Zacks) -6.43%
Apr-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
12:00PM	Loading…
Mar-26-25 12:00PM	All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy (Zacks) -6.63%
Mar-20-25 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) +6.69%
Mar-09-25 10:03AM	This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street (Motley Fool)
Feb-26-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-25-25 08:05AM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
03:00AM	Its CEO died. The company scrapped a promising program. Now, for their 2nd act. (Pharma Voice)
Feb-24-25 04:05PM	Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire) -6.87%
Feb-20-25 04:05PM	Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Feb-05-25 04:05PM	Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-03-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-25 04:05PM	Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.84%
Jan-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-16-24 01:10PM	Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
04:05PM	Loading…
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire) -7.62%
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire) -5.44%
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.08%
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool) +6.02%
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire) +23.14%
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire) +16.77%
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)
Jul-20-24 09:30AM	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? (Motley Fool)
Jun-21-24 06:30PM	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation (GlobeNewswire)
Jun-19-24 01:27PM	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue? (Zacks)
Jun-04-24 09:55AM	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade (Zacks)
Jun-03-24 04:10PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-30-24 08:05AM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-24 04:05PM	Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day (GlobeNewswire) +5.93%
May-13-24 01:53PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 (InvestorPlace) +5.94%
09:32AM	Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections (GuruFocus.com)
08:05AM	Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 04:05PM	Terns Pharmaceuticals Announces Leadership Changes (GlobeNewswire) +5.03%
May-07-24 04:05PM	Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 (GlobeNewswire)
May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.43%
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23% +7.30%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69% -6.26%
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13% +9.81%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire) +6.97%
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire) +5.96%
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -13.73%
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -6.80%
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire) +5.17%
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16% -23.52%

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kuriakose Emil	Chief Medical Officer	Jul 01 '25	Sale	4.27	853	3,640	52,464	Jul 03 02:55 PM
Gengos Andrew	Chief Financial Officer	Jun 27 '25	Buy	3.93	10,000	39,283	25,000	Jun 30 05:38 PM
Burroughs Amy L.	Chief Executive Officer	Jun 25 '25	Buy	3.87	23,314	90,230	47,083	Jun 25 06:08 PM
Gengos Andrew	Chief Financial Officer	Jun 13 '25	Buy	3.73	10,000	37,350	10,000	Jun 16 06:05 PM
Gengos Andrew	Chief Financial Officer	Jun 16 '25	Buy	3.95	5,000	19,732	15,000	Jun 16 06:05 PM
Kuriakose Emil	Chief Medical Officer	Apr 01 '25	Sale	2.49	952	2,366	53,317	Apr 02 06:48 PM
Jung Melita Sun	Chief Business Officer	Nov 30 '24	Buy	5.11	2,250	11,498	2,250	Feb 03 07:28 PM
Burroughs Amy L.	Chief Executive Officer	Nov 30 '24	Buy	5.11	510	2,606	19,609	Feb 03 07:25 PM
Kuriakose Emil	Chief Medical Officer	Jan 02 '25	Sale	5.71	4,481	25,607	54,269	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 06 '25	Sale	5.80	9,059	52,500	74,752	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 02 '25	Sale	5.72	8,129	46,524	83,811	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 06 '25	Sale	5.79	8,760	50,758	0	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 02 '25	Sale	5.72	6,240	35,702	8,760	Jan 06 07:30 PM
MARK J VIGNOLA	Officer	Jan 06 '25	Proposed Sale	5.75	9,059	52,089		Jan 06 04:29 PM
JILL QUIGLEY	Director	Jan 06 '25	Proposed Sale	5.75	8,760	50,370		Jan 06 04:29 PM
Burroughs Amy L.	Chief Executive Officer	Dec 05 '24	Buy	7.15	15,450	110,468	19,099	Dec 09 06:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience